ArticleNature2022
The longitudinal dynamics and natural history of clonal haematopoiesis.
Abstract read
In one paragraph
Article in Nature, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 266 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
266citing papers in PubMed, 2 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
266 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Somatic and germline genetic testing pathways in haematological malignancies: Best practice consensus guidelines from the 2025 national meeting organised by UK Cancer Genetics Group (UKCGG), CanGene-CanVar and the NHS England Haematological Oncology Working Group.British journal of haematology · 2026Guideline
- Clinical impact of clonal hematopoiesis in hematopoietic cell transplantation: a review, meta-analysis, and call to action.Haematologica · 2024Pooled it
- Colchicine and Longitudinal Dynamics of Clonal Hematopoiesis: An Exploratory Substudy of the LoDoCo2 Trial.Journal of the American College of Cardiology · 2025Trial
- Genomic and Epigenomic ctDNA Profiling in Liquid Biopsies from Heavily Pretreated Patients with DNA Damage Response-Deficient Tumors.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Trial
- Dynamics of clonal hematopoiesis under DNA-damaging treatment in patients with ovarian cancer.Leukemia · 2024Trial
- Efferocytosis activates a DNMT3A-mediated oxidized DNA repair pathway to enable tissue resolution.The Journal of clinical investigation · 2026Article
- Germline homologous recombination deficiency influences TP53-mutant clonal hematopoiesis fitness during platinum and PARP inhibitor treatment.Nature genetics · 2026Article
- Long-term mutational analysis, clonal metrics, and dynamics in patients with chronic idiopathic neutropenia.HemaSphere · 2026Article
- Disentangling Heterogeneous Molecular Networks for Multi-Omics-Driven Cancer Driver Discovery.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- SRSF2 P95H induces monocytic priming of human hematopoietic stem and progenitor cells.Leukemia · 2026Article
- Tumor, germline, and paired testing in oncology: practical considerations.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- The Evolution of Polyclonal Competition in Aging Hematopoiesis.Cancer discovery · 2026Article
- Loss of Function Dnmt3a Mutation Leads to Aberrant Neutrophil Migration.Experimental hematology · 2026Article
- Genetic influences on haematopoiesis.Nature reviews. Genetics · 2026Review
- Longitudinal characterization of mosaic chromosomal alterations identifies factors influencing clonal dynamics of leukocytes.Nature communications · 2026Article
- Evolution of clonal hematopoiesis during cancer treatment and its impact on outcomes.The Journal of clinical investigation · 2026Article
- Statin Use and Genetically Predicted HMG-CoA Reductase Inhibition in Relation to Clonal Hematopoiesis.medRxiv : the preprint server for health sciences · 2026Article
- Aldehyde Detoxification in Cancer: Metabolic Guardians of the Genome.Biomolecules · 2026Review
- Clonal hematopoiesis of indeterminate potential (CHIP)-a pivotal contributor of aging and related disorders.Annals of translational medicine · 2026Review
- Clonal hematopoiesis in the setting of sickle cell disease and its relevance to curative therapies.Seminars in hematology · 2026Article
206 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
21 authors.
Margarete A Fabre *Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, UK.
José Guilherme de Almeida *European Molecular Biology Laboratory, European Bioinformatics Institute EMBL-EBI, Wellcome Genome Campus, Cambridge, UK.
Edoardo FiorilloIstituto di Ricerca Genetica e Biomedica, Consiglio Nazionale delle Ricerche, Lanusei, Italy.
Emily MitchellWellcome Sanger Institute, Wellcome Genome Campus, Cambridge, UK.
Aristi DamaskouWellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, UK.
Justyna RakWellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, UK.
Valeria OrrùIstituto di Ricerca Genetica e Biomedica, Consiglio Nazionale delle Ricerche, Lanusei, Italy.ORCID http://orcid.org/0000-0002-6047-4625
Michele MarongiuIstituto di Ricerca Genetica e Biomedica, Consiglio Nazionale delle Ricerche, Lanusei, Italy.ORCID http://orcid.org/0000-0002-7289-9815
Michael Spencer ChapmanWellcome Sanger Institute, Wellcome Genome Campus, Cambridge, UK.ORCID http://orcid.org/0000-0002-5320-8193
M S VijayabaskarWellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, UK.
Joanna BaxterCambridge Blood and Stem Cell Biobank, Department of Haematology, University of Cambridge, Cambridge, UK.
Claire HardyWellcome Sanger Institute, Wellcome Genome Campus, Cambridge, UK.
Federico AbascalWellcome Sanger Institute, Wellcome Genome Campus, Cambridge, UK.ORCID http://orcid.org/0000-0002-6201-1587
Nicholas WilliamsWellcome Sanger Institute, Wellcome Genome Campus, Cambridge, UK.ORCID http://orcid.org/0000-0003-3989-9167
Jyoti NangaliaWellcome Sanger Institute, Wellcome Genome Campus, Cambridge, UK.ORCID http://orcid.org/0000-0001-7122-4608
Iñigo MartincorenaWellcome Sanger Institute, Wellcome Genome Campus, Cambridge, UK.ORCID http://orcid.org/0000-0003-1122-4416
Peter J CampbellWellcome Sanger Institute, Wellcome Genome Campus, Cambridge, UK.ORCID http://orcid.org/0000-0002-3921-0510
Eoin F McKinneyCambridge Institute of Therapeutic Immunology & Infectious Disease, University of Cambridge, Cambridge, UK.
Francesco CuccaIstituto di Ricerca Genetica e Biomedica, Consiglio Nazionale delle Ricerche, Lanusei, Italy.
Moritz GerstungEuropean Molecular Biology Laboratory, European Bioinformatics Institute EMBL-EBI, Wellcome Genome Campus, Cambridge, UK. moritz.gerstung@dkfz.de.ORCID http://orcid.org/0000-0001-6709-963X
George S VassiliouWellcome Sanger Institute, Wellcome Genome Campus, Cambridge, UK. gsv20@cam.ac.uk.ORCID http://orcid.org/0000-0003-4337-8022
Funding
Cancer Research UK 21777Cancer Research UK 23015Cancer Research UK 23917European Research CouncilMedical Research Council MC_PC_17230NIDA NIH HHS HHSN271201100005CWellcome TrustWellcome Trust 098051Wellcome Trust 104064/Z/14/Z
Abstract
Clonal expansions driven by somatic mutations become pervasive across human tissues with age, including in the haematopoietic system, where the phenomenon is termed clonal haematopoiesis
Indexed as
Clonal HematopoiesisClone CellsAgedAgingGenome, HumanHumansLongitudinal StudiesMiddle AgedMutationPhylogeny
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.